BJDX
Bluejay Diagnostics, Inc.
NASDAQ · USHealthcareMedical - Devices
$1.21-16.55%
Price as of Jul 20, 2026
BJDX financials
Bluejay Diagnostics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $249.0K |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $200.1K |
| Gross profit | $0.00 | $0.00 | $0.00 | $48.9K |
| Operating expenses | $7.0M | $7.2M | $10.3M | $9.4M |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.3M |
| Net income | -$6.8M | -$7.7M | -$10.0M | -$9.3M |
| EBITDA | -$6.7M | -$6.7M | -$9.2M | -$9.0M |
| Basic EPS | $-15.25 | $-456.76 | $-290.48 | $-292.88 |
| Diluted EPS | $-15.25 | $-456.76 | $-290.48 | $-292.88 |
| Balance sheet | ||||
| Cash & equivalents | $5.2M | $4.3M | $2.2M | $10.1M |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M |
| Total liabilities | $1.1M | $927.9K | $2.0M | $2.0M |
| Stockholders’ equity | $6.0M | $5.7M | $2.9M | $11.5M |
| Total debt | $120.2K | $222.2K | $353.0K | $492.6K |
| Net debt | -$5.0M | -$4.1M | -$1.9M | -$9.6M |
| Cash flow | ||||
| Operating cash flow | -$6.1M | -$7.8M | -$8.3M | -$7.7M |
| Capital expenditure | -$173.7K | -$306.8K | -$704.2K | -$1.2M |
| Free cash flow | -$6.2M | -$8.1M | -$9.0M | -$8.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |